WO2003053960A3 - Quinline derivates and their use as mek inhibitors - Google Patents

Quinline derivates and their use as mek inhibitors Download PDF

Info

Publication number
WO2003053960A3
WO2003053960A3 PCT/GB2002/005518 GB0205518W WO03053960A3 WO 2003053960 A3 WO2003053960 A3 WO 2003053960A3 GB 0205518 W GB0205518 W GB 0205518W WO 03053960 A3 WO03053960 A3 WO 03053960A3
Authority
WO
WIPO (PCT)
Prior art keywords
quinline
derivates
mek inhibitors
containment
medicament
Prior art date
Application number
PCT/GB2002/005518
Other languages
French (fr)
Other versions
WO2003053960A2 (en
Inventor
Laurent Francois And Hennequin
Keith Hopkinson Gibson
Kevin Michael Foote
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Laurent Francois And Hennequin
Keith Hopkinson Gibson
Kevin Michael Foote
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd, Laurent Francois And Hennequin, Keith Hopkinson Gibson, Kevin Michael Foote filed Critical Astrazeneca Ab
Priority to AU2002356276A priority Critical patent/AU2002356276A1/en
Publication of WO2003053960A2 publication Critical patent/WO2003053960A2/en
Publication of WO2003053960A3 publication Critical patent/WO2003053960A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention concerns quinoline derivatives of Formula (I) wherein each of Z, m, R1, n and R3, X, Y and W have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.
PCT/GB2002/005518 2001-12-05 2002-12-05 Quinline derivates and their use as mek inhibitors WO2003053960A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002356276A AU2002356276A1 (en) 2001-12-05 2002-12-05 Quinline derivates and their use as mek inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0129099.8 2001-12-05
GBGB0129099.8A GB0129099D0 (en) 2001-12-05 2001-12-05 Chemical compounds

Publications (2)

Publication Number Publication Date
WO2003053960A2 WO2003053960A2 (en) 2003-07-03
WO2003053960A3 true WO2003053960A3 (en) 2003-09-12

Family

ID=9927037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/005518 WO2003053960A2 (en) 2001-12-05 2002-12-05 Quinline derivates and their use as mek inhibitors

Country Status (3)

Country Link
AU (1) AU2002356276A1 (en)
GB (1) GB0129099D0 (en)
WO (1) WO2003053960A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877776B2 (en) 2009-01-16 2014-11-04 Exelixis, Inc. (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US9359332B2 (en) 2002-07-15 2016-06-07 Symphony Evolution, Inc. Processes for the preparation of substituted quinazolines

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2272737T3 (en) 2001-07-16 2007-05-01 Astrazeneca Ab DERIVATIVES OF QUINOLINA AND ITS USE AS INHIBITORS OF THYROSINE KINASES.
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
GB0225579D0 (en) 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
PL2210607T3 (en) 2003-09-26 2012-01-31 Exelixis Inc N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
DE102007024470A1 (en) 2007-05-24 2008-11-27 Bayer Schering Pharma Aktiengesellschaft New sulfoximine-substituted quinoline and/or quinazoline derivatives are erythropoietin-producing hepatoma amplified sequence-receptor kinase inhibitors useful to prepare medicaments to e.g. treat endometriosis and stenosis
EP2072502A1 (en) 2007-12-20 2009-06-24 Bayer Schering Pharma Aktiengesellschaft Sulfoximide substituted chinolin and chinazolin derivatives as kinase inhibitors
UA108618C2 (en) 2009-08-07 2015-05-25 APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
CU24272B1 (en) 2012-03-14 2017-08-08 Lupin Ltd TETRAHYDROPIRID-PYRIMIDINE DERIVATIVES AS MEK INHIBITORS
WO2016009306A1 (en) 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors
WO2016035008A1 (en) 2014-09-04 2016-03-10 Lupin Limited Pyridopyrimidine derivatives as mek inhibitors
WO2017062500A2 (en) 2015-10-05 2017-04-13 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
CN113620874B (en) * 2021-08-10 2024-02-06 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2-trifluoromethyl-4-amino-quinoline derivatives and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043960A1 (en) * 1997-04-03 1998-10-08 American Cyanamid Company Substituted 3-cyano quinolines
WO2000018761A1 (en) * 1998-09-29 2000-04-06 American Cyanamid Company Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043960A1 (en) * 1997-04-03 1998-10-08 American Cyanamid Company Substituted 3-cyano quinolines
WO2000018761A1 (en) * 1998-09-29 2000-04-06 American Cyanamid Company Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9359332B2 (en) 2002-07-15 2016-06-07 Symphony Evolution, Inc. Processes for the preparation of substituted quinazolines
US8877776B2 (en) 2009-01-16 2014-11-04 Exelixis, Inc. (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

Also Published As

Publication number Publication date
GB0129099D0 (en) 2002-01-23
AU2002356276A1 (en) 2003-07-09
WO2003053960A2 (en) 2003-07-03
AU2002356276A8 (en) 2003-07-09

Similar Documents

Publication Publication Date Title
HK1063185A1 (en) Quinoline derivatives and their use as tyrosine kinase inhibitors
MY127369A (en) Quinazoline derivatives
WO2006063841A3 (en) Trycyclic heterocycles, their manufacture and use as pharmaceutical agents
MY129809A (en) Quinazoline derivatives
IL170120A (en) 1,2,4-triazine compounds, their use for preparation of medicaments for treating or preventing hiv, pharmaceutical compositions comprising the same and processes for their preparation
WO2004056828A3 (en) Novel compounds and uses thereof
SE0202539D0 (en) Compounds
WO2003095455A3 (en) Substituted pyrazolopyrimidines
TW200624431A (en) Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
ATE409185T1 (en) QUINAZOLINE DERIVATIVES
WO2003053960A3 (en) Quinline derivates and their use as mek inhibitors
WO2006108488A8 (en) Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
AU2003281193A1 (en) Quinazoline derivatives for use in the treatment of cancer
TW200420567A (en) Quinazoline derivatives
AU2003290127A1 (en) 4-amino-7,8-dihydropteridines, pharmaceutical compositions containing them and their use for the treatment of diseases which are caused by an increased nitric oxide level
AU2003259986A1 (en) Pharmaceutical compositions
SE0202693D0 (en) Compounds
SE0202692D0 (en) Compounds
WO2007054139A3 (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
WO2003024996A3 (en) Antibacterial macrocycles
TW200736220A (en) Pyridylsulfonamide derivatives, their manufacture and use as pharmaceutical agents
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
TW200612914A (en) Novel oxidized thioether derivatives, their manufacture and use as pharmaceutical agents
TW200505913A (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
TW200633701A (en) Thioether derivatives, their manufacture and use as pharmaceutical agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP